Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mycolic acid biosynthesis enzyme complex refers to a group of enzymes and associated proteins responsible for the production of mycolic acids—very long-chain α-alkyl, β-hydroxy fatty acids that are essential components of the cell wall in mycobacteria, including Mycobacterium tuberculosis. This complex is critical for bacterial viability and virulence, making its biosynthetic machinery a prime target for anti-tuberculosis drug development. Key components include FAS-I, FAS-II (KasA/KasB, MabA, InhA, HadAB/HadBC), FadD32, Pks13, and CmrA, as well as various modifying enzymes. These enzymes form dynamic multi-enzyme complexes on ACP scaffolds to facilitate efficient substrate channeling and coordinated modification events during synthesis. The pathway is transcriptionally regulated, and disrupting any part can lead to loss of cell wall integrity or death in Mtb strains.
Inhibition of mycolic acid biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycolic Acid Biosynthesis Enzyme Complex (None).